GAVI to roll out a record-low price for HPV vaccines
A record-low price for HPV vaccines has been negotiated by GAVI for countries eligible for support, opening the door for millions of girls in the world’s poorest countries to be immunised against the human papilloma virus (HPV) – the cause of virtually all forms of cervical cancer. The $4.50 vaccine represents a two-thirds drop on the lowest current available public price.
Every 2 minutes, a woman dies from cervical cancer and the vast majority, over 85% of the 275,000 annual deaths each year, are in developing countries where access to screening and treatment is often limited. Cervical cancer is the leading cause of cancer deaths among women in the 50+ countries eligible for GAVI support. The tragedy is that cervical cancer is preventable. HPV vaccines coupled with screening and treatment, can prevent the rising tide of this disease.
GAVI’s support for HPV vaccines will enable a bridging of the gap between rich and poor countries, by making HPV vaccines available where girls need them the most, and preventing the infection that causes this disease.
Over the coming months, eight mainly sub-Saharan African countries, will be the first to introduce HPV vaccines with GAVI support. Ghana, Kenya, Lao PDR, Madagascar, Malawi, Niger, Sierra Leone and the United Republic of Tanzania will run demonstration programmes to test the best ways to deliver HPV vaccines to adolescent girls with other interventions that benefit their lives. Rwanda will be the first country to roll out HPV vaccines nationally with GAVI support in 2014.
By 2015, GAVI plans to support the vaccination of one million girls in more than 20 countries and expects these numbers to accelerate dramatically, with the goal of more than 30 million girls vaccinated in over 40 countries by 2020.
For more information and to access GAVI's official Press Release, click here: http://bit.ly/10j7Dz3